ArticleEBioMedicine2019

A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer.

Richard Tuli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.